Market Cap (In USD)
78.87 Million
Revenue (In USD)
-
Net Income (In USD)
-13.07 Million
Avg. Volume
152.17 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.11-20.72
- PE
- -4.73
- EPS
- -0.56
- Beta Value
- 0.0
- ISIN
- US87975F1049
- CUSIP
- -
- CIK
- 1971532
- Shares
- 29762670.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Erez Aminov
- Employee Count
- -
- Website
- https://telomirpharma.com
- Ipo Date
- 2019-04-09
- Details
- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
More Stocks
-
TIP
-
HUMLHumble Energy, Inc.
HUML
-
4310Dream Incubator Inc.
4310
-
3245Dear Life Co.,Ltd.
3245
-
BTTC
-
NKLANikola Corporation
NKLA
-
ROSTRoss Stores, Inc.
ROST
-
PZZA